A better speculation might have been piling in to many extra shares down around $7. I'd bought a few extra shares, but didn't have enough guts to go nuts.
I agree that Gizzmo still looks cheap, but I think where you make the real money in this sector is loading up on crazy cheap. $7 was obviously crazy cheap. Of course, you have to have the cash ready, and you have to be correct, and patient. Although I had bought extra shares of Gizzmo while it was down, for a few days I even had 10,000 extra shares on top of that. Alas, I did not own those shares on the day Gizzmo recovered, but I still can't complain.
GZTC on the other hand seems to be the only Genzyme baby which supports a decent marketcap. I wonder if that isn't becuase Transgenics is the only one in which Genzyme is only a minority owner?
I have some extra money in several stocks which I hope are crazy cheap. But just an average sized position in Gizzmo now. Of course once you get into some of these biotechs, you don't ever dare sell that core position. Cure a few cancers and pretty soon you're talking real money. Gizzmo has as good a chance as any biotech out there, I agree that recent SAGE news seemed pretty huge. Why the stock is being held here at $12, I don't know, but it has flatlined...for now.
I did end up selling the wife's shares, hemmed and hawed, but I'm trying to stay a quarter to a third cash in both our accounts. Sacrifizing her Gizzmo after this recent bounce back was the only way to do it.
Now I just have to wait for some more crazy cheap to come my way again. Maybe $12 is still far too low for the shares, but who can really say. We do know that there is an awful lot of biotech product online now, way too many IPOs etc. Don't know how the analysts can pimp all of it at the same time. So I like cash too these days. |
